HANNA, ASHRAF NPI 1619948429 Clinician
Pain Management · CLEARWATER, FL
- SPINECARE ASSOCIATES, LLC — CLEARWATER, FL
Group affiliation since 2019
The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.
Year: 2024 · 2023 · 2022 locked column · 2021 locked column · 2020 locked column
Provider overview · all codes · CY2024
The full analytics for this provider
PremiumThe billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.
- Charge, service & beneficiary totals — the disclosed scale, all codes
- Practice profile — focus & reach — top codes by share of services
- Office vs. facility setting mix — place-of-service code split
- Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
- Peer positioning — code breadth — how many codes billed, vs peers
Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.
Notify me at launch → Or see a live example profile →Procedures billed to Medicare Part B (2024)
Medicare Part B FFS · CY2024 · as published by CMS| Code | Description | Volume locked column | Beneficiary-episodes locked column | Avg charge locked column | Avg Medicare payment locked column |
|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | premium | premium | premium | premium |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | premium | premium | premium | premium |
| J3490 | Unclassified drugs | premium | premium | premium | premium |
| 99214 | Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | premium | premium | premium | premium |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | premium | premium | premium | premium |
| 96375 | Injection of additional new drug or substance into vein | premium | premium | premium | premium |
| 99213 | Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more | premium | premium | premium | premium |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | premium | premium | premium | premium |
| J3475 | Injection, magnesium sulfate, per 500 mg | premium | premium | premium | premium |
| 80305 | Testing for presence of drug, read by direct observation | premium | premium | premium | premium |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | premium | premium | premium | premium |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | premium | premium | premium | premium |
| 20550 | Injection into tendon or ligament | premium | premium | premium | premium |
| 96130 | Evaluation of psychological test, first hour | premium | premium | premium | premium |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | premium | premium | premium | premium |
| J7050 | Infusion, normal saline solution, 250 cc | premium | premium | premium | premium |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | premium | premium | premium | premium |
| 76942 | Ultrasonic guidance for needle placement | premium | premium | premium | premium |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | premium | premium | premium | premium |
| 96374 | Injection of drug or substance into vein | premium | premium | premium | premium |
| 93041 | Electrocardiogram (ecg) 1 to 3 leads | premium | premium | premium | premium |
| 64640 | Destruction of peripheral nerve or branch | premium | premium | premium | premium |
| 64636 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | premium | premium | premium | premium |
| 64450 | Injection of anesthetic agent and/or steroid into other nerve or branch | premium | premium | premium | premium |
| 99204 | New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more | premium | premium | premium | premium |
| 20610 | Aspiration and/or injection of fluid from large joint | premium | premium | premium | premium |
| 64635 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | premium | premium | premium | premium |
| 20552 | Injection of trigger points, 1-2 muscles | premium | premium | premium | premium |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | premium | premium | premium | premium |
| 64493 | Injection of lower or sacral spine facet joint using imaging guidance, single level | premium | premium | premium | premium |
| J2550 | Injection, promethazine hcl, up to 50 mg | premium | premium | premium | premium |
| 64494 | Injection of lower or sacral spine facet joint using imaging guidance, second level | premium | premium | premium | premium |
| 96372 | Injection of drug or substance under skin or into muscle | premium | premium | premium | premium |
| 64625 | Destruction of nerves supplying joint between spine and pelvis using imaging guidance | premium | premium | premium | premium |
| 64634 | Destruction of upper or middle spinal facet joint nerves using imaging guidance, each additional facet joint | premium | premium | premium | premium |
| 62323 | Injection of substance into lower spine canal using imaging guidance | premium | premium | premium | premium |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | premium | premium | premium | premium |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | premium | premium | premium | premium |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | premium | premium | premium | premium |
| 64483 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | premium | premium | premium | premium |
| 62321 | Injection of substance into middle or upper spine canal using imaging guidance | premium | premium | premium | premium |
| 64490 | Injection of upper or middle spine facet joint using imaging guidance, single level | premium | premium | premium | premium |
| 64491 | Injection of upper or middle spine facet joint using imaging guidance, second level | premium | premium | premium | premium |
| 64633 | Destruction of upper or middle spinal facet joint nerves using imaging guidance, single facet joint | premium | premium | premium | premium |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | premium | premium | premium | premium |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | premium | premium | premium | premium |
| 20553 | Injection of trigger points, 3 or more muscles | premium | premium | premium | premium |
| 64405 | Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | premium | premium | premium | premium |
| 64484 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | premium | premium | premium | premium |
These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.